Medistem and ERCell Initiate Phase II RECOVER-ERC Heart Failure Trial MarketWatch (press release) SAN DIEGO, CA, Jan 30, 2012 (MARKETWIRE via COMTEX) -- Medistem Inc. (pinksheets:MEDS) together with its Russian Licensee, ERCell LLC, announced successful dosing of 3 heart failure patients in the Non-Revascularizable IschEmic Cardiomyopathy treated ... |
